Abstract
Since last few years genetic testing has become easily available. In developing countries where cost may forbid testing, evaluating clinical exome sequencing(CES) might be financially more feasible than whole exome sequencing (WES) for heterogenous mendelian disorders. However there are few studies to assess diagnostic yield of CES. Our study looked at diagnostic yield of clinical exome panel for phenotypic subgroup of neurological disorder with a presumed genetic aetiology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have